Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... (PRWEB) May 06, 2015 Histogen, ... on the products of cells grown under simulated ... 105F immunomodulatory treatment candidate for melanoma during the ... taking place May 6-9, 2015 in Atlanta, GA. ... cells produce a soluble material with anti-oncologic properties, ...
(Date:5/5/2015)... /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) ("Aptose" ... three months ended March 31, 2015 and provided a ... Canadian dollars. Effective July 17, 2014 ... 31 to December 31. As a result of that ... the three months ended March 31, 2015, while the ...
(Date:5/5/2015)... , May 05, 2015 Research ... has announced the addition of the ... to their offering. Macromolecules which ... undergo separation or are broken into smaller ... products. This separation requires various advanced systems ...
(Date:5/5/2015)... , May 5, 2015 Reprints Desk, Inc., ... providing on-demand access to scientific, technical and medical (STM) ... the Association of Southeastern Research Libraries (ASERL) . ... libraries located across 11 southeastern states. Founded in 1956, ... collaborative programs to address the continually changing needs of ...
Breaking Biology Technology:Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4
... As previously announced on October 24th, 2009 delSECUR CORPORATION sold ... del-Id system to QTech Systems Inc. in an Asset Purchase ... time and as mentioned in the Press Release on June ... on the del-Id prototype development for commercialization. ...
... 4, 2011 Reportlinker.com announces that a ... its catalogue: Antiviral Therapeutics ... http://www.reportlinker.com/p0203535/Antiviral-Therapeutics---Technologies-markets-and-companies.html ... antiviral approaches including vaccines, pharmaceuticals and innovative ...
... Reportlinker.com announces that a new market research ... Nanobiotechnologies- applications, markets and companies ... is the creation and utilization of materials, devices, ... the nanometer-length scale (a nanometer is one billionth ...
Cached Biology Technology:delSECUR CORPORATION Announces Its Dissolution; and the Distribution of Its Asset to Its Lenders and Shareholders of the Corporation 2Reportlinker Adds Antiviral Therapeutics - Technologies, Markets and Companies 2Reportlinker Adds Antiviral Therapeutics - Technologies, Markets and Companies 3Reportlinker Adds Antiviral Therapeutics - Technologies, Markets and Companies 4Reportlinker Adds Nanobiotechnologies - Applications, Markets and Companies 2Reportlinker Adds Nanobiotechnologies - Applications, Markets and Companies 3
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/2/2015)... 2015 Fingerprint Cards (FPC) has ... from the distributor World Peace Industrial Group (WPI), part ... although the major part of the shipments will take ... by smartphone manufacturers in China . ... the communicated revenue guidance of + 1 000 MSEK for ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... at Buffalo has been shown to extend significantly the survival ... cancer's spread to the lungs in the animals by more ... particular disaccharide, an antigen known as TF-Ag, which aids the ... antibody did not kill the cancer cells, it blocked stages ...
... Researchers have uncovered physiological differences among female Glanville ... from their birth place and establish new colonies. ... more quickly compared to their less mobile female ... how genetic differences influence behavior and how the ...
... at the Stowers Institute for Medical Research, and Olivier ... the Howard Hughes Medical Institute, are the first and ... network of cyclic genes that shed light on the ... , The paper was published on Science Express, ...
Cached Biology News:Antibody extends life of mice with breast cancer 2Some butterflies travel farther, reproduce faster 2Some butterflies travel farther, reproduce faster 3
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
...
... Immunogen: Synthetic peptide derived from the C-terminal ... growth factor D iris-expressed growth factor spinal ... mouse and rat by one amino acid ... kDa human mouse and rat PDGF-D proteins. ...
...
Biology Products: